Table 1. Clinical characteristics at baseline.
| ART naïve | ART-treated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALL | Arm 1 (COX-2i 4 months) | Arm 2 (COX-2i 2 weeks) | Arm 3 (No COX-2i) | Arms 2/3 | Arm 1 vs. Arm 2/3 | ALL | Arm 1 (COX-2i 4 months) | Arm 2 (COX-2i 2 weeks) | Arm 3 (No COX-2i) | Arms 2/3 | Arm 1 vs. Arm 2/3 | |
| N | 28 | 13 | 7 | 8 | 15 | p-value | 28 | 13 | 8 | 7 | 15 | p-value |
| CD4 T cell count (cells/mL) | 529 (477–696)1 | 493 (450–545) | 643 (562–819) | 595 (465–1036) | 643 (509–819) | 0.042 | 364 (288–444) | 321 (228–379) | 362 (309–415) | 443 (344–523) | 384 (340–458) | 0.07 |
| CD4/CD8 ratio | 0.46 (0.30–0.58) | 0.39 (0.30–0.47) | 0.57 (0.40–0.64) | 0.58 (0.35–0.70) | 0.57 (0.40–0.64) | 0.03 | 0.48 (0.35–0.62) | 0.46 (0.30–0.48) | 0.57 (0.43–0.63) | 0.53 (0.35–0.99) | 0.54 (0.39–0.65) | 0.10 |
| Plasma HIV RNA (copies/mL) | 24000 (10750–84000) | 35000 (14000–85000) | 20000 (1700–83000) | 24000 (12850–105500) | 22000 (8700–83000) | 0.66 | <50 | <50 | <50 | <50 | <50 | 1.0 |
| Nadir CD4 T cell count (cells/mL) | 496 (438–595) | 491 (441–545) | 547 (452–590) | 522 (393–628) | 531 (425–622) | 0.56 | 169 (115–233) | 139 (64–226) | 155 (118–210) | 231 (180–249) | 200 (136–234) | 0.39 |
| Age (years) | 41 (38–43) | 42 (39–43) | 41 (34–49) | 40 (36–41) | 41 (34–42) | 0.25 | 44 (40–53) | 48 (41–51) | 44 (39–49) | 43 (42–57) | 43 (39–54) | 0. 91 |
| Gender (M/F) | 25/3 | 12/1 | 7/0 | 6/2 | 13/2 | n.s.3 | 26/2 | 12/1 | 7/1 | 7/0 | 14/1 | n.s. |
| Time since HIV diagnosis (years) | 2.1 (1.0–5.3) | 1.9 (0.8–5.1) | 3.1 (0.4–5.5) | 2.2 (1.3–4.6) | 2.4 (1.2–5.5) | 0.63 | 6.4 (3.4–10.7) | 5.7 (2.7–10.7) | 3.9 (3.4–9.4) | 8.2 (5.5–12.0) | 6.8 (3.5–9.4) | 0.73 |
| Time on ART (years) | - | - | - | - | - | 4.3 (2.4–6.5) | 4.8 (2.6–5.6) | 3.1 (1.7–5.4) | 6.0 (2.5–7.9) | 3.73 (2.3–7.0) | 0.50 | |
1Data given as median and lower/upper quartile
2 Mann-Whitney U test
3 Chi-square test